College programs that leave graduates underpaid or buried in loans would be cut off from federal money under a proposal issued by the Biden administration on Wednesday

By Suzanne McGee Bitcoin, the original crypto rebel, is racing into the heart of the financial establishment with

Growing up, people are generally taught that taking vitamins is good for you, with many people taking supplements to boost their intake. However, results of a new study suggest that taking vitamins could actually have a negative impact on health as they may help tumours to grow. New research suggests that taking additional vitamins and minerals, including common antioxidants such as vitamins A and C, and selenium and zinc, could help the blood vessels in tumours to grow. The study was conducted by scientists at the Karolinska Institutet in Sweden who published their findings in the Journal of Clinical Investigation. The results were somewhat of a surprise to experts, who believed anti-oxidants to be protective of the body. In their research, they found that vitamin C and other antioxidants actually stimulated the formation of new blood vessels in lung cancer tumours. Martin Bergö, who is a professor at the Department of Biosciences and Nutrition, said: “We’ve found that antioxidants activate a mechanism that causes cancer tumours to form new blood vessels, which is surprising since it was previously thought that antioxidants have a protective effect. “The new blood vessels nourish the tumours and can help them grow and spread.” Antioxidants, in normal amounts, neutralise free oxygen radicals that damage the body, so are beneficial. But, scientists found that high doses of antioxidants can activate a protein called BACH1 which begins the formation of new blood vessels, allowing harmful tumours to grow. Bergö explained: “There’s no need to fear antioxidants in normal food but most people don’t need additional amounts of them. “In fact, it can be harmful for cancer patients and people with an elevated cancer risk.” Ting Wang, the study’s lead author, said: “Many clinical trials have evaluated the efficacy of angiogenesis inhibitors, but the results have not been as successful as anticipated. “Our study opens the door to more effective ways of preventing angiogenesis in tumours; for example, patients whose tumours exhibit high levels of BACH1 might benefit more from anti-angiogenesis therapy than patients with low BACH1 levels.” Sign up to our free Indy100 weekly newsletter Have your say in our news democracy. Click the upvote icon at the top of the page to help raise this article through the indy100 rankings.

By Sam Tobin and Paul Sandle LONDON Microsoft on Tuesday accused Britain's anti-trust regulator of being a global

Facebook-parent Meta on Wednesday officially launched its Twitter competitor, Threads, after first confirming its plans for the app just three months ago.

Sean Newman had an elaborate plan to propose to his long-time love Janice Dean 15 years ago but nothing quite went the way he wanted

A federal judge will not block Microsoft from closing its $69 billion deal to acquire video game giant Activision Blizzard, a defeat for US regulators who had asked for a temporary injunction while legal challenges to the merger unfold.

(Reuters) -Daimler Truck expects revenues to grow as much as 60% between 2025 and 2030, top management of the truck

LONDON--(BUSINESS WIRE)--May 22, 2023--

A caterer who pretended to be a plastic surgeon has been arrested after performing a fatal penis enlargement on a 'patient'. Torben K, a 46-year-old man from Solingen, Germany, administered silicone injections into the victim's penis and scrotum area. He reportedly refused to disclose the type of silicone oil. The 32-year-old patient died from sepsis seven months after the procedure in July 2019. An investigation found that Torben had no medical qualifications and previously carried out the same procedure on another man earlier in the year. Judges in Wuppertal District Court found Torben guilty of causing death by grievous bodily harm. The sister of the unnamed victim said her brother had doubts about the treatment but Torben convinced him to go ahead. He was said to experience breathing difficulties as soon as he returned home. The man reportedly visited several hospitals but later died of blood poisoning and liver and kidney failure. Speaking to local media, High State Prosecutor Wolf-Tilman Baumert said: "Unfortunately, the silicone oil ended up in the person's bloodstream. This led to severe health complications and, eventually, to his death." Torben claimed he had only done what the patient requested, to which Baumert responded: "The fact that the man asked for the treatment is irrelevant from our point of view. The defendant acted in a highly immoral manner." Torben was jailed for five years, though the verdict is not yet legally binding. Sign up for our free Indy100 weekly newsletter Have your say in our news democracy. Click the upvote icon at the top of the page to help raise this article through the indy100 rankings.

Threads, Instagram’s answer to Twitter, is finally here. After months of rumours, and amid what seems like it could be the decline of Twitter, Meta has launched its own platform for posting short text updates and replying to those from others. The app arrived overnight and is already picking up momentum, gaining ten million of downloads and signups in its first few hours. But what is it actually like to use, and will it be the thing that finally takes over from Twitter? Here are some first impressions of using the app, in the first few hours it is available. First impressions: Signing up and following people The sign-up process is astonishingly slick, in large part because of the app’s integration with Instagram. (So if you don’t use Instagram already, it won’t be quite so impressive.) This is already an important contrast with other Twitter competitors, such as Mastodon and Bluesky, which have complicated signup processes that could very easily put off potential users. Signing up means downloading the app, clicking your already imported Instagram login, and then choosing which of the accounts you follow there to copy over to Threads. Once that is done, you will be taken to the news feed. From there, everything will look very familiar: it is a combination of Twitter and Instagram, and that’s exactly what it looks like. If you’ve used those apps, you’ll probably already have a perfect sense of how it works, and even if you haven’t then everything is built to be as obvious and intuitive as possible. What is Threads like to use? The Threads app is astonishingly neat, and it already puts Twitter to shame. Everything is nicely sized to ensure that you can read posts and scroll through them, and the news feed is easy to navigate through. It is, mostly, like one of the third-party clients for Twitter, which Elon Musk killed off soon after he took over the site. Just like them, you get the basic functions of Twitter – replies, profiles and so on – but repackaged into a much nicer design. One of the big problems will be deciding who to follow from Instagram. Being able to post nice pictures on there is in no way an indication of a person’s ability to write nice text updates, and many of the best posters on Twitter would have been useless on a picture-focused site. When I open up Threads, for instance, it has a large focus on the kind of organisational account that I tend to follow for their nice pictures on Instagram. Those accounts are not necessarily quite so fun in text form. The other big problem is that the app is a lot less useful until people actually start signing up. If you don’t follow people already, then the feed will instead try to fill itself with posts from others, picked via an algorithm; just as it does on Instagram, that algorithm tends to pick quite boring and not especially relevant posts. An app like Threads – just like Instagram and Twitter before it – are only really as good as the people you follow. For now, there are fewer people to follow, and so it’s hard to say exactly how good or bad the app might end up being. Will Threads kill Twitter? Many apps have tried to succeed Twitter. Many have failed. But Threads is stronger than those that have come before, and Twitter is weaker than it has ever been. So the fact that no app has yet unseated Twitter does not mean that it is doomed. Much of that strength comes in the backing of Meta. It means that the app is slick and highly functional at launch, and comes with an existing network of people imported from Instagram. And much of the weakness of Twitter comes from timing. The site has gone from problem to problem under Elon Musk – but feels particularly troubled at the moment, after a weekend that saw a flurry of technical issues that brought with them an unusual response. However, Twitter has long served an unusual function in society, far beyond its actual size. Celebrities and major organisations have used it to make announcements; the media has used it to report on them. That importance within society meant that it stuck around long after its users became frustrated with it (and was probably the reason Mr Musk bought it in the first place). But that importance has already been disappearing: as a result of technical issues, a falling reputation and more, many of the individuals and organisations that gave Twitter its value have already left. It’s very likely that no other app will ever be able to recreate the combination of societal heft and blazing speed that marked Twitter out at its best. Not even Twitter can really do that anymore. It’s unlikely that Twitter will actually die soon: social networks tend to die not with a bang but with a whimper, and there will be probably be people that stick around long after the site has lost its place in society. But it is safe to say that it is already shrinking, and that Threads could accelerate that. So Threads might eventually kill Twitter: it already has a better design, and is less likely to prove controversial, and looks well set up to take users from its competitor site. But it might also not actually need to kill Twitter, which is dying already and might never be replaced. Read More Threads: What it’s like to use Instagram’s new Twitter rival Meta’s new Twitter rival app Threads gets over 5 million sign-ups How to get and use ‘Threads’, the biggest new social app Mark Zuckerberg launches his ‘Twitter killer’ app called Threads Judge blocks Biden agencies from communicating with social media platforms Meta’s Twitter alternative Threads to be launched this week

U.S. District Judge Analisa Torres said Ripple Labs Inc’s institutional sales of its XRP digital token violated federal